How do you spell relief?
For Johnson & Johnson (NYSE:JNJ), which has been battered for months by a series of recalls involving its over-the-counter pharma products (including Rolaids), it’s not D-E-S.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
How do you spell relief?
For Johnson & Johnson (NYSE:JNJ), which has been battered for months by a series of recalls involving its over-the-counter pharma products (including Rolaids), it’s not D-E-S.
No matter how many times Smith & Nephew (NYSE:SNN) says it’s not talking merger, somebody else says it is.
The neuromodulation medical device company Intelect Medical Inc. recently left its Cleveland headquarters for Boston. Now it may be in for a departure of another order — namely, an exit.
Medicare not currently sustainable. Financial analysis shows that what people paid into the federally-funded healthcare system doesn’t come close to covering the full value of the medical care they can expect to receive as retirees, reports the Associated Press.
Updated: 12/17/2010 1:30 p.m.
Lawsuits over recalled hip implants made by Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopedics are being consolidated under a federal district court judge in Ohio.
The multi-district litigation is slated to take place in the U.S. District Court for Northern Ohio under Judge David Katz, according to Montgomery, Ala.-based law firm Beasley Allen.*
MRI ananlysis detects autism. A McClean Hospital neuroimaging researchers distinguished people with autism from control subjects 94 percent of the time using a magnetic resonance imaging scan that took about 10 minutes, reports the The Boston Globe‘s White Coat Notes blog.
By MassDevice
FDA’s top criminal investigator resigns amidst scrutiny. Terry Vermillion told the Food & Drug Administration that he would step down as head of the agency’s Office of Criminal Investigations, where he served for 18 years, about two months after a whistleblower made allegations about the alteration of internal agency reports and other ethical violations, according to The Wall Street Journal.
The chief executives of healthcare companies are among the best paid in industry, according to a Wall Street Journal survey.
Boston Scientific Corp. (NYSE:BSX) CEO Raymond Elliott ranked eighth on the newspaper’s list, earning $32.1 million last year. That’s a princely sum to be sure, but includes a hefty signing bonus and other, long-term awards.
Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc Casper edged Elliott out for the seventh spot with $33.0 million in 2009